JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $25
Author: Benzinga Newsdesk | May 09, 2025 10:01am
JMP Securities analyst David Turkaly maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $35 to $25.